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Human rhinovirus (HRV) replicons have the potential to serve as respiratory vaccine vectors for mucosal immunization in
humans. However, since many vaccine immunogens of interest are glycosylated, an important concern is whether HRV
replicons are capable of expressing glycosylated proteins. The human respiratory syncytial virus (RSV) fusion (F) protein was
chosen as a model glycoprotein and the HRV replicon DP1FVP3 was generated by inserting the F protein-coding sequence
in frame and in lieu of the 59 proximal 1489 nucleotides of the capsid-coding segment in the HRV-14 genome. When
transfected into H1-HeLa cells, DP1FVP3 replicated and led to the expression of the F protein. Inhibition with guanidine
demonstrated that F-protein expression was dependent on DP1FVP3 replication and did not result from translation of input
RNA. Although most of the F protein remained as an immature, glycosylated precursor (F0), a readily detectable fraction of
the protein was processed into the mature glycosylated subunit F1, an event known to occur within the Golgi apparatus.
Packaged DP1FVP3 replicons were generated in transfected HeLa cells by coexpression of homologous HRV capsid proteins
using the vaccinia virus/T7 RNA polymerase hybrid system. Packaged replicon RNAs were capable of infecting fresh cells,
leading to accumulation of the F protein as in RNA-transfected cells. Mice immunized with HeLa cell lysates containing F
protein expressed from DP1FVP3 produced neutralizing antibodies against RSV. These results indicate that an HRV-14
replicon can express a foreign glycosylated protein, providing further support for the potential of HRV replicons as a vaccine
delivery system. © 2001 Academic Press
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The human rhinoviruses (HRVs) constitute a large
group of over 100 antigenically distinct serotypes within
the picornavirus family. HRVs replicate within epithelial
cells and adjacent lymphoid tissues of the upper respi-
ratory tract of humans, and natural infection with HRV is
an effective stimulus for production of both local mucosal
IgA and systemic IgG antibodies to the virus (Couch,
1996). We have reported previously on the generation of
subgenomic HRV replicon RNAs in which the luciferase
reporter gene replaced most of the capsid (P1) coding
sequence in HRV-14 (McKnight and Lemon, 1996, 1998).
HRV replicons express the viral proteins required for
RNA replication and are efficiently amplified following
transfection into permissive cells. We have also demon-
strated that HRV replicons can be packaged when the P1
protein precursor is provided in trans by coinfection with
intact helper virus. Taken together, these findings sug-
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216gest that packaged HRV replicons could function as
efficient vectors for the expression of foreign proteins in
the mucosal environment of the human airway.
As members of the Picornaviridae, the HRVs are non-
enveloped positive-stranded RNA viruses. The approxi-
mate 7200-nt HRV RNA genome contains a single open
reading frame (ORF). An internal ribosomal entry site
(IRES) located in the 59 nontranslated (NTR) RNA of the
enome controls the cap-independent translation of the
ingle polyprotein that is subsequently processed into
ndividual gene products by two virally encoded protein-
ses, 2A and 3C(D) (see Fig. 1A). Based on the proteo-
ytic processing scheme, the polyprotein can be divided
nto three segments: P1, P2, and P3. The P1 segment
omprises the structural or capsid proteins, while P2 and
3 contain the nonstructural proteins required for repli-
ation of the RNA genome (Fig. 1A).
Several research groups have explored the possibility
f configuring picornavirus chimeras or replicons as vac-
ine vectors for expression of foreign proteins (Alex-
nder et al., 1994; Andino et al., 1994; Choi et al., 1991;
Lemon et al., 1992). The different systems that have been
evaluated include antigen chimeras that incorporate
epitopes from different viruses in surface loops of HRV
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217RSV F PROTEIN EXPRESSION USING AN HRV VECTORand PV coat proteins (Arnold et al., 1994; Dedieu et al.,
992; Girard et al., 1995; Lemon et al., 1992; Smith et al.,
998). Another approach includes the construction of
odified, mono- or dicistronic PV RNA genomes. In the
onocistronic configuration, foreign sequences are
used either between the IRES and the P1 segment, or
FIG. 1. Structural organization of the HRV-14 genome, HRV-14 repl
infectious cDNA clone of HRV-14, pWR3.26. The open reading frame is
viral proteases 2A and 3C/3CD. The capsid precursor P1 (shaded box
cis-acting replication element (cre) within the HRV-14 genome is indicat
The gene for the RSV F protein (solid box) is inserted directly after the 5
by a synthetic viral 3CDpro cleavage site, is incorporated at the 39 term
f the HRV-14 polyprotein. (C) Schematic representation of the pDFex
escribed in the text are indicated. (D) Linear structure and domain orga
1 and F2, as well as the positions of the signal sequence, hydropho
leavage by signal peptidase and furin protease. Large arrowheads ind
ng to the location of the anti-peptide antibody RF78 is shown.etween the P1 and the P2 segments (Altmeyer et al.,
994, 1995; Andino et al., 1994; Crotty et al., 1999; Girard
t
rt al., 1995; Tang et al., 1997; Van der Ryst et al., 1998; Yim
t al., 1996). These constructs rely on proteolytic pro-
essing of the foreign protein by the viral proteinases 2A
r 3C(D). In contrast, foreign sequence in the dicistronic
onfiguration is translated under control of the poliovirus
PV) IRES while the PV polyprotein is placed under con-
1FVP3, and the RSV F protein. (A) Schematic representation of the
d into precursor protein regions P1, P2, and P3 that are processed by
aved into capsid proteins VP4, VP2, VP3, and VP1. The location of the
striped box. (B) Organization of the HRV-14 derived replicon DP1FVP3.
and upstream of the VP3/VP1 junction. A triple glycine hinge, followed
f the F gene to facilitate cleavage of the F protein from the remainder
pDFmutexp F-protein expression vectors. Stop codons engineered as
n of the RSV F protein (Collins et al., 1996). Shown are the two domains,
ion, and transmembrane domains. Small arrows indicate the sites of
e glycosylation sites. In addition, the amino acid position correspond-icon DP
divide
) is cle
ed by a
9 NTR
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equirement for proteolytic processing of the foreign pro-
c
b
1
u
r
(
218 DOLLENMAIER ET AL.tein (Alexander et al., 1994; Lu et al., 1995). Although
monocistronic PV recombinants were able to induce
humoral immune responses against different immuno-
gens (Andino et al., 1994; Crotty et al., 1999; Tang et al.,
1997; Yim et al., 1996), this system is limited by the
maximal size of the insert and the stability of the modi-
fied genome during replication (Mueller and Wimmer,
1998). Another vector construction, used in the present
study, utilizes picornavirus subgenomic replicons in
which heterologous protein-coding sequence replaces
the capsid-coding region, P1, and is fused in frame to the
remainder of the viral polyprotein coding sequence
(Anderson et al., 1996, 1997; Choi et al., 1991; McKnight
and Lemon, 1998). In the replicon configuration, the for-
eign protein is cleaved from the polyprotein by one of the
two viral proteases (for example, see Fig. 1B). Since
replicons do not express the structural proteins, they
cannot spread from cell to cell. This strategy tends to
maximize insert integrity, as genomes that would have
lost heterologous sequences are not expanded by sec-
ond-round infections. Picornavirus replicons can be
packaged by providing capsid proteins in trans (e.g., by
oinfection with helper virus or by using a vaccinia virus-
ased expression system (Ansardi et al., 1993; Jia et al.,
998; and this study)). Packaged PV replicons have been
sed in several studies and demonstrate that picornavi-
us replicons have strong potential as vaccine vectors
Anderson et al., 1996, 1997; Ansardi et al., 1994; Basak et
al., 1998; Moldoveanu et al., 1995).
Based on previous work with PV and our own work
with HRV replicons (McKnight and Lemon, 1996, 1998),
we hypothesized that HRV-14 replicons may serve as
unique and efficient vectors for mucosal immunization in
humans. There are several potential advantages for us-
ing HRV replicons in mucosal immunizations: (i) since
HRVs naturally target the upper respiratory tract of hu-
mans, HRV-based vaccine vectors are likely to be effec-
tive in stimulating protective mucosal immunity, (ii) HRV
infections are associated with relatively low pathogenic-
ity, and (iii) current efforts at worldwide eradication of
poliomyelitis make the use of PV-based replicons poten-
tially problematic.
Since many medically important immunogens are gly-
cosylated, it is important to determine whether an HRV-
based vaccine vector can express glycoproteins. We
therefore selected the fusion (F) protein of respiratory
syncytial virus (RSV) for the present study. RSV, a mem-
ber of the paramyxovirus family, is the most common
cause of bronchiolitis and pneumonia among children
under one year of age in the United States. RSV infection
causes about 90,000 hospitalizations and 4500 deaths
per year from lower respiratory tract disease (Institute of
Medicine, 1985). Candidate vaccines including formalin-
inactivated RSV and subunit vaccines have been devel-
oped, but do not provide effective protection against RSV
infection (Collins et al., 1996). Thus, there is a criticalneed for an effective and safe vaccine against RSV in-
fection.
The F protein is a well-defined major neutralization
antigen of RSV and contains several conformational
epitopes that can induce protective immune responses
(Collins et al., 1996). Alterations of the tertiary structure of
the F protein during vaccine preparation may have been
one of the reasons that vaccination studies using forma-
lin-inactivated virus or affinity-purified F protein were not
successful (Gotoh et al., 1992). Therefore, it is speculated
that the F protein needs to be generated in its mature,
processed, and glycosylated form to be able to induce a
virus-neutralizing protective immune response (Sakurai
et al., 1999). This is supported by the work of Olmstead et
al. (1986) and Wertz et al. (1987), who showed that F
protein expressed from a recombinant vaccinia virus that
is fully processed and glycosylated is capable of induc-
ing a protective immune response against RSV chal-
lenge in a mouse model.
During the RSV replication cycle, the F protein is syn-
thesized as a glycosylated 68- to 70-kDa F0 precursor
that is processed during its transport through the Golgi
compartment by a cellular proteinase into the mature
disulfide linked F1 (49 kDa) and F2 (20 kDa) subunits
(see Fig. 1D) (Collins et al., 1984; Collins and Mottet,
1991). The F2 subunit contains an N-terminal signal se-
quence that is cleaved by signal peptidase (type 1 trans-
membrane protein), while the C-terminal transmembrane
domain within the F1 subunit anchors the protein into the
host cell membrane (Collins et al., 1984). Furthermore,
the F1 and F2 subunits contain, respectively, one and
four potential acceptor sites for N-linked carbohydrate
side chains, which are all used for glycosylation (Fig.
1D).
In this report we describe the construction and eval-
uation of a recombinant HRV-14 replicon DP1FVP3 in
which the 59 one-third of the P1 segment has been
replaced with the entire RSV F protein coding sequence.
The residual, downstream HRV P1 sequence is retained
in the replicon as it contains the cre (cis-acting replica-
tion element), a signal necessary for replication of the
HRV-14 RNA (McKnight and Lemon, 1996, 1998). We
demonstrate that this replicon is replication competent,
and characterize the physical attributes and immuno-
genic activity of the F protein expressed from DP1FVP3
RNA in H1-HeLa cells. Our findings support the idea that
HRV replicons can be configured to successfully express
glycosylated immunogens, and have potential for further
development as a vaccine delivery system in the human
airway.
RESULTS
Construction of candidate replicon DP1FVP3The candidate replicon DP1FVP3 was generated by
inserting the cDNA sequence encoding the F protein of
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219RSV F PROTEIN EXPRESSION USING AN HRV VECTORRSV Long strain in lieu of the 59 one-third of the capsid
(P1)-coding segment of the full-length HRV-14 sequence
contained in the plasmid pWR3.26 (Fig. 1). The F coding
sequence was inserted in pWR3.26 such that the 59 end
f F gene sequence was fused to the authentic AUG
nitiation codon of the HRV-14 IRES, with the 39 end fused
n frame at nt 2117 of the HRV-14 P1 segment (Fig. 1B). To
llow for efficient processing of the F protein, an artificial
RV-14 3CDpro cleavage site (A–x-x-Q/G) was engineered
t the 39 terminus of the F sequence, downstream of a
riple glycine hinge that was included to allow flexibility
f the peptide chain to optimize cleavage potential (Fig.
B). The efficient processing of this cleavage site in the
ontext of the luciferase-encoding replicon DP1LucVP3
as been described previously (McKnight and Lemon,
996). This modification resulted in the extension of the
ytoplasmic tail of the F protein by seven additional
mino acids. To maintain replication competency, it was
ecessary to retain the HRV-14 cre containing sequence
in the DP1FVP3 construct (McKnight and Lemon, 1992,
1996), which maps to nt 2317 to 2413 of the P1 segment.
The RNA transcribed from pDP1FVP3 is 260 nt (3.5%)
longer than the infectious HRV-14 RNA genome.
Analysis of DP1FVP3 replication
The extent to which modified picornavirus genomes
are able to express foreign glycoproteins that carry a
signal sequence is not clear. Previous studies by Lu et al.
(1995) indicated that dicistronic PV genomes encoding
secreted proteins with a signal sequence from the T-cell
receptor, CD4, were blocked at the level of RNA replica-
tion. Furthermore, inhibition of the cellular secretory
pathway by PV proteins 2B and 3A poses further limita-
tions to the ability of the PV system to express secreted
proteins (Aldabe et al., 1996; Barco and Carrasco, 1995;
Doedens et al., 1997; Doedens and Kirkegaard, 1995),
and this may also be the case for HRV. However, the
successful expression of a glycosylated envelope sur-
face proteins of simian immunodeficiency virus using
monocistronic PV replicons has been reported (Ander-
son et al., 1996; Tang et al., 1997). The RSV F protein
contains a cleaved signal sequence at its N-terminus
and a C-terminal transmembrane domain that stops the
transfer of the polypeptide chain into the lumen of the ER
(Fig. 1D). In the context of the HRV replicon, the stop-
transfer activity of the anchorage domain should result in
the cytoplasmic localization of the C-terminus of the F
protein and the downstream HRV-14 polyprotein. This
configuration should allow efficient recognition and pro-
cessing of the engineered 3CDpro cleavage site in
P1FVP3 by the viral protease and the release of the
RV-14 polyprotein to the cytosol.
To determine whether the DP1FVP3 replicon was ableo replicate following transfection in H1-HeLa cells,
NAs representing DP1LucVP3, DP1Luc, and DP1FVP3
i
cere transfected into H1-HeLa cells and cellular lysates
ere assayed for HRV-14 RNA at the indicated times
ollowing transfection by ribonuclease protection assay
Fig. 2). In this experiment, the DP1LucVP3 replicon
erved as a positive control while the nonreplicating
P1Luc replicon (which lacks the cre sequence) served
s a negative control. In order to monitor the cellular RNA
ontent of the lysates, an RNA that corresponds to the
uman glyceraldehyde-3-phosphate dehydrogenase
GAPDH) was included as a second probe.
As shown in Fig. 2, the amount of HRV-14-specific RNA
n lysates of DP1LucVP3 and DP1FVP3 transfected cells
ncreased during the 24 h following transfection, indicat-
ng successful replication of these RNAs. These results
ontrast sharply with the level of protected RNA ob-
erved following transfection with the nonreplicating
P1Luc RNA. The presence of probe-specific high-mo-
ecular-weight bands at the later time points has been
eported previously; these most likely represent pro-
ected RNA hybrids that have escaped the denaturation
onditions of the gel (McKnight and Lemon, 1996, 1998).
hen the amount of protected HRV-14 RNA was normal-
FIG. 2. Ribonucleic protection assay of DP1FVP3 RNA replication in
H1-HeLa cells. Cell lysates were collected at 0, 6, 12, and 24 h following
transfection with DP1LucVP3 and DP1FVP3 replicon RNAs or from
mock-transfected cells. Virus-specific RNA was detected by hybridiza-
tion with an excess of HRV-14-specific probe (HRV) followed by RNase
treatment and denaturing polyacrylamide gel electrophoresis (PAGE).
The cellular RNA content of each lysate was monitored by an internal
control probe hybridizing to glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). The left lane contains 1:100 the amount of each probe
used in individual hybridization reactions. Protected fragments specific
for virus (263 nt) and for GAPDH (100 nt) are indicated with arrows.zed to the amount of protected GAPDH RNA, the repli-
ation of the DP1FVP3 RNA was found to be only slightly
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220 DOLLENMAIER ET AL.reduced when compared to the DP1LucVP3 replicon
(data not shown). Thus, the HRV-14 replicon DP1FVP3
that contains the RSV F glycoprotein sequence is able to
replicate to levels equivalent to that of the DP1LucVP3
replicon (Fig. 2). This result indicates that the coding
sequence from a foreign protein with an N-terminal sig-
nal sequence and a C-terminal stop-transfer domain can
be inserted into the HRV-14 ORF without disrupting rep-
lication of the replicon RNA.
Immunoblot analysis of F-protein expression following
transfection of DP1FVP3 RNA
We next determined whether the F protein was being
expressed from the DP1FVP3 replicon and whether post-
translational processing of the F protein had occurred.
Cellular lysates were prepared from H1-HeLa cells 24 h
following transfection with DP1Luccre (a successfully rep-
licating HRV-14 replicon that expresses luciferase) and
DP1FVP3 RNAs. Proteins were analyzed by immunoblot
using monoclonal antibody RF78, which is specific for
amino acids 269–277 of the F1 subunit of the F protein
(Fig. 1D). Lysates from RSV-infected or mock-infected
HEp-2 cells were used as positive and negative controls,
respectively (Fig. 3A, lanes 1 and 2). In lysates from
RSV-infected cells, the RF78 antibody specifically de-
tected a major protein of approximately 48 kDa that
corresponded to the expected molecular mass of 49 kDa
for the glycosylated F1 subunit of the F protein (Fig. 3A,
lane 2). A second specific protein of approximately 24
kDa was present at an abundance similar to that of the
F1 subunit. This protein may represent a degradation
product of the F protein. Because the RSV-infected HEp-2
cells were harvested late in infection (2 days postinfec-
tion), the F protein was completely processed and there-
fore no F0 precursor (69 kDa) could be detected. Analy-
sis of lysates from DP1FVP3-transfected H1-HeLa cells
revealed two major specific proteins when compared to
DP1Luccre or mock-transfected cells (Fig. 3A, lane 5 vs.
lanes 3 and 4). The dominant protein migrated with an
apparent molecular mass of 66 kDa, consistent with the
expected size of 69 kDa for the glycosylated F0 precur-
sor (Collins et al., 1984). A lesser, faint band of approxi-
mately 48 kDa comigrated with the RSV F1 subunit (Fig.
3A, lanes 2 and 5). These results suggest that there is at
least partial processing of the F0 precursor into the F1
and F2 subunits in the Golgi apparatus in cells trans-
fected with DP1FVP3 RNA.
It could be argued that the failure to completely pro-
cess the DP1FVP3-expressed F0 precursor is due to the
presence of the additional seven amino acids fused to
the C-terminus of the F protein following proteolytic pro-
cessing by rhinovirus 3CDpro (Fig. 1B). Therefore, we
constructed two bacteriophage T7 expression vectors
that could be used to document the extent in which
mutant F protein expressed from the DP1FVP3 vectorcould undergo processing into F1 and F2. Derived from
the DP1FVP3 replicon, pDFexp contains the F protein
under translational control of the HRV-14 IRES. A stop
codon was engineered after the last amino acid (aa) of
the F-protein coding sequence, which is immediately
followed by the 39 NTR and poly(A) tract from the vector
mut
FIG. 3. Expression of F protein in DP1FVP3, pDFexp, or pDFmutexp
transfected and DP1FVP3 virion infected H1-HeLa cells. (A) H1-HeLa
cells were transfected with replicon RNAs (lanes 3 to 5) or infected with
30 ml of a packaged replicon stock (lanes 6 to 8) and cellular lysates
ere analyzed 24 h later by SDS–12% PAGE and immunoblot as
escribed under Materials and Methods. Lysates from HEp-2 cells
ollected 48 h after RSV infection served as positive control (lanes 1, 2).
he molecular weight marker is indicated on the left and positions of
ifferent F-protein species (F0 precursor and F1 subunit) are shown on
he right. Mock, lysates from mock-transfected or mock-infected cells.
B) H1-HeLa cells were transfected with pDFexp (lane 1) or pDFmutexp
lane 2) plasmids and superinfected with 5 m.o.i. of vTF73 and cellular
ysates were analyzed 24 h later by SDS–8% PAGE and immunoblot as
n Fig. 3A. Lysates from mock-transfected and vTF73-infected cells
lane 3) and lysates from RSV-infected Hep-2 cells (lane 4) served as
egative and positive controls, respectively. Note that vaccinia virus
as been shown previously not to block F-protein expression and
rocessing (Olmstead et al., 1986; Wertz et al., 1987).(Fig. 1C). pDF exp was similarly constructed except
that it contains the seven additional aa fused to the F
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221RSV F PROTEIN EXPRESSION USING AN HRV VECTORprotein following processing of the DP1FVP3 polyprotein
(Fig. 1C).
H1-HeLa cells were transfected with either pDFexp
or pDFmutexp plasmid DNA and infected with vaccinia
irus expressing the bacteriophage T7 RNA polymer-
se (vTF73) as described under Materials and Meth-
ds. Cell lysates were harvested for immunoblot anal-
sis 24 h following transfection and infection. As
hown in Fig. 3B, the F protein produced from both
xpression vectors was able to undergo complete
rocessing, as indicated by the appearance of only the
1 subunit in lanes 1 and 2 of the immunoblot. Only a
ery faint amount of the F0 precursor could be seen
pon longer exposure of this blot (data not shown).
hus, the additional C-terminal aa fused to the F pre-
ursor expressed from DP1FVP3 have no effect on its
rocessing into F1 and F2.
mmunoblot analysis of F-protein expression following
ackaged replicon (vDP1FVP3) infection
We also assessed the expression of the F protein in
ells infected with packaged replicon RNAs. Packaged
NA was generated in a vaccinia virus/bacteriophage T7
NA polymerase hybrid expression system as described
nder Materials and Methods and by Jia et al. (1998). We
initially characterized the efficiency of this packaging
system using the luciferase-expressing replicon
DP1Luccre. Replicon packaging efficiency was docu-
ented by following luciferase activity and by in situ
mmunostaining of cells infected with packaged replicon
NA. Luciferase activity could be completely blocked by
retreatment of packaged replicon RNA stocks with an-
ibodies against HRV-14. Average titers of packaged rep-
icon stocks ranging between 0.5 and 2 3 105 luciferase-
expressing cells per milliliter could be routinely approx-
imated from cell monolayers immunostained with
luciferase antibody (see Materials and Methods; and
data not shown).
To verify F-protein expression from packaged replicon
RNA, H1-HeLa cells were infected with the packaged
DP1FVP3 and DP1Luccre RNAs (vDP1FVP3 and
DP1Luccre, respectively). Cellular lysates were prepared
4 h following infection and subjected to immunoblot
nalysis as described above (Fig. 3A, lanes 6–8). Cells
hat had been infected with vDP1FVP3 expressed a
anel of immunoreactive proteins identical to those in
he DP1FVP3 RNA-transfected cells. This result indicates
hat the DP1FVP3 RNA had been successfully packaged
nto virions and that these virions were able to deliver the
eplicon RNA into the infected cell (Fig. 3A, lane 7). In
ontrast, control cells infected with packaged lysates
rom DP1Luccre RNA (vDP1Luccre) and mock-infected
cells did not contain a comparable panel of immunore-
active proteins (lanes 6 and 8).In situ analysis of vDP1FVP3-infected cells
expressing F protein
To further confirm the expression of the F protein in
H1-HeLa cells, indirect immunofluorescence staining
was carried out on cells that were infected with
vDP1FVP3. In contrast to cells that were infected with
vDP1Luccre or that were mock-infected (Figs. 4C and 4D,
respectively), a strong fluorescent signal was present in
30–50% of the vDP1FVP3-infected cells, indicating the
successful infection of a substantial proportion of the
cells and the resulting expression of the F protein, which
was present primarily in the cytoplasm (Figs. 4A and 4B).
The fluorescent signal observed from the packaged viri-
ons was equivalent to that observed from transfected
replicon RNAs (data not shown), indicating that there is
little difference in the amount of expressed F protein
derived from these two methods of replicon RNA deliv-
ery. We also performed confocal fluorescent microscopy
on cells transfected with DP1FVP3 RNA and found lim-
ited immunostaining of F protein on the cell membrane
(data not shown).
Time course analysis of DP1FVP3 expression of the F
protein
We examined the expression of the F0 and F1 proteins
in H1-HeLa cells in a time course experiment. Cells were
transfected with DP1FVP3 RNA, or mock-transfected with
PBS only, and lysates were prepared at the time points
indicated in Fig. 5. Equal amounts of the lysates were
subjected to immunoblot analysis as described for Fig. 3.
As shown in Fig. 5A, the F0 precursor and the F1 subunit
began to accumulate as early as 9 h post-transfection
with F0 as the predominant protein species. Coinci-
dently, this is within the initial time point when replication
of the transfected DP1FVP3 RNA is being detected (com-
pare between the 6- and 12-h time points in the gel of Fig.
2), suggesting that F-protein expression is linked to RNA
replication because at this time point there would be
more RNA available for translation. The amounts of both
the F1 and the F0 proteins were significantly increased
by the 14-h time point; however, the relative proportion of
both proteins remained constant during this period (com-
pare lanes 5 and 7). By 24 h, the overall expression of F0
and F1 appeared somewhat reduced but an abundant
amount of F1 could still be detected. Densitometric scan-
ning of the F-specific bands in Fig. 5A, as well as immu-
noblots from additional experiments, indicated that F1
represented 20–35% of the detectable F protein (data not
shown), indicating the extent of processing by the furin-
like protease located in the trans-Golgi compartment.
The overall reduction in F-protein expression at the 24-h
time point may be due to shutdown of cellular vesicular
transport by this time following transfection. However,
we did not observe a consistent amount of the pro-
cessed F1 protein in every experiment, suggesting that
and
ivalent
222 DOLLENMAIER ET AL.other factors may contribute to the reduced F-protein
expression, such as variable transfection efficiencies or
cell conditions. Similarly, there could be some inconsis-
tencies in the transfer of proteins onto nitrocellulose in
the different blotting experiments.
We also examined the time-dependent expression of F
protein following infection with encapsidated DP1FVP3
RNA. The results of this experiment are shown in Fig. 5B.
The appearance of the F0 precursor was similar to what
was observed in the RNA transfection experiment de-
picted in Fig. 5A (compare lanes 5 and 7 in both). How-
ever, the overall expression of the F protein from the
packaged virions was consistently lower than that ob-
served from transfection of RNA (compare Figs. 5A to
5B). This is likely due to the fact that the packaged virions
were not titered and that a smaller proportion of cells
were infected than the proportion undergoing successful
transfection of RNA. By comparing in situ staining of cells
transfected with DP1FVP3, we have noted a higher per-
centage of cells expressing F protein (50–70%, data not
shown) than in cells infected with vDP1FVP3 (30–50%,
Figs. 4A and 4B).
Taken together, these data indicate that the F protein
FIG. 4. In situ detection of F-protein expression by indirect immunof
DP1FVP3 virions and 16 h after infection F-protein expression was d
Methods. (A, B) Infection with DP1FVP3 virions at magnifications of 103
mock infection. The apparent packaging efficiency of DP1FVP3 was equis expressed from the DP1FVP3 replicon in RNA-trans-
fected or virion-infected cells. At 9, 14, and 23 h followingtransfection or infection, the uncleaved F0 precursor pro-
tein represented the major F-specific protein species,
whereas smaller amounts of the mature F1 subunit could
also be detected. This indicates that a readily detectable
amount of post-translational modification of the F protein
was taking place in the Golgi compartment.
Expression of the F protein is dependent on DP1FVP3
RNA replication
The results in Figs. 4 and 5 clearly indicate that the
DP1FVP3 replicon expresses the F protein. However, this
expression could be related only to the initial translation
of the input RNA only, and could be blocked at later times
following transfection when replication of the replicon
RNA has induced shutdown of the cellular vesicular
transport pathway. To determine whether F-protein ex-
pression was dependent on replication of DP1FVP3 RNA,
we monitored the expression of F protein in transfected
cells treated with guanidine hydrochloride (GuHCl).
Treatment of cells with millimolar concentrations of Gu-
HCl is known to block the synthesis of picornavirus RNA
but does not interfere with picornaviral translation (Bar-
ence. H1-HeLa cells on chamber slides were infected with packaged
by indirect immunofluorescence as described under Materials and
203, respectively. (C) Infection with packaged DP1Luccre virions or (D)
to that observed with the reporter DP1Luccre replicon (data not shown).luoresc
etectedton and Flanegan, 1997; Caliguiri and Tamm, 1968). As
shown in Fig. 6, at later times (9, 14, and 24 h) following
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RNA is otherwise maximal (see Fig. 2), no expression of
the F protein was detected in lysates from cells treated
with GuHCl (lanes 3, 5, and 7 in Fig. 6). In contrast, in
lysates from cells transfected in the absence of GuHCl
treatment, expression of the F protein increased during
the 24 h following transfection, as observed in previous
experiments (compare lanes 2, 4, and 6 of Fig. 6 to the
results in Fig. 5). We also observed little or no expression
of F protein during earlier times following transfection (3
and 6 h) in the presence of GuHCl, indicating that trans-
lation of the F protein from input RNA alone was likely
FIG. 5. Time-dependent expression of F protein in DP1FVP3 RNA-con
or (B) infected with packaged DP1FVP3 replicon RNA. Cellular lysates
roteins were analyzed as described in Fig. 3. The F1 protein present
ell growth during the 24 h following electroporation, the nonspecific s
arker and the different F-protein species (F0 precursor and F1 subun
esults. p.t., post-transfection; p.i., postinfection.below the level of detection in the immunoblot (compare
in Fig. 5; and data not shown). These results confirm that
c
tthe observed expression of the F protein is dependent on
replication of DP1FVP3 RNA.
F protein expressed by the DP1FVP3 replicon is
glycosylated
The apparent electrophoretic mobility of the F0 and
F1 proteins expressed by DP1FVP3 corresponded to
the expected molecular masses of the respective gly-
cosylated proteins (Collins et al., 1984). To determine
xperimentally whether these proteins were indeed
lycosylated, lysates from H1-HeLa cells taken 15 h
ollowing transfection with the DP1FVP3 replicon and
H1-HeLa cells. H1-HeLa cells (A) were transfected with DP1FVP3 RNA
repared 4, 9, 15, and 24 h following transfection or infection. F-specific
-infected HEp-2 cell lysates was used as a control. Due to continued
cellular proteins also increases at later times. The molecular weight
shown as in Fig. 3A. This experiment was repeated twice with similartaining
were p
in RSV
ignal toontrol lysates from RSV-infected cells were subjected
o treatment with PNGase F or endoglycosidase H
l
o
H
224 DOLLENMAIER ET AL.(endo H) and analyzed by immunoblot (Fig. 7). PNGase
F is a glycoamidase with broad specificity that sepa-
rates almost all N-linked oligosaccharides from glyco-
proteins. In contrast, endo H has a more limited sub-
strate specificity and prefers high-mannose and hybrid
oligosaccharide side chains that are characteristic for
the endoplasmic reticulum (Kobata, 1979; Tarentino et
al., 1985).
As shown in Fig. 7A, PNGase F treatment of RSV-
infected cell lysates caused a shift in electrophoretic
mobility of the F1 protein that corresponded to a reduced
molecular mass of approximately 2.7 kDa (Fig. 7A, lanes
2 and 3). This observation is consistent with the fact that
one carbohydrate chain is predicted to contribute 2.1 kDa
FIG. 6. Expression of the F protein is dependent on replication of
DP1FVP3 RNA. Immediately following electroporation, H1-HeLa cells
were placed in normal media (2) or media containing 2 mM GuHCl (1).
At 9, 14, and 24 h following transfection, cell lysates were subjected to
SDS–10% PAGE and analyzed by immunoblot for analysis of F-protein
expression. p.t., post-transfection.
FIG. 7. Enzymatic deglycosylation of F protein. Lysates from H1-HeLa
ysates from RSV-infected HEp-2 cells were subjected to glycosidase
r endo H, the proteins were separated by SDS–12% PAGE and analyzed by im
1-HeLa cells following transfection with DP1FVP3 RNA.to the molecular mass of a glycoprotein and that the F1
subunit only contains one acceptor site for N-linked
carbohydrates (Fig. 1D; Collins et al., 1996). Treatment of
the lysates with endo H did not alter the mobility of F1
(Fig. 7A, lanes 4 and 5). This observation is in agreement
with earlier findings that the maturating F protein ac-
quires resistance to endo H attack during its transport
through the trans-Golgi compartment and is indicative of
proper glycosylation of the protein (Collins and Mottet,
1991).
When lysates from DP1FVP3-transfected cells were
subjected to PNGase F digestion, the apparent molecu-
lar mass of the dominant F0 precursor protein was re-
duced by approximately 12.5 kDa, indicating that all five
carbohydrate side chains were removed by the enzyme
(Fig. 7B, lanes 2 and 3). Following treatment with endo H,
the F0-specific band was shifted to the same molecular
mass as seen after PNGase F treatment (compare lanes
3 and 5 of Fig. 7B). The susceptibility of F0 to the endo H
suggested that this protein accumulated in compart-
ments prior to the trans-Golgi compartment. In contrast,
the minor F1 band was not reduced in mass by endo H
digestion, although its mass was reduced approximately
2.5 kDa by treatment with PNGase F. These results
indicate that the F1 expressed from the replicon was
glycosylated in a fashion similar to the native viral pro-
tein shown in Fig. 7A.
The results from Fig. 7 indicate that the DP1FVP3
replicon is able to express the F protein in a glycosylated
form. The major protein species represented the imma-
ture glycosylated F0 precursor protein, whereas the ma-
ture F1 subunit that was properly processed and glyco-
sylated was present in much smaller amounts.
collected 15 h after transfection with the DP1FVP3 replicon, or control
nt (1) or mock-treated (2). After overnight incubation with PNGase Fcells,
treatmemunoblot. (A) Lysates from RSV-infected HEp-2 cells. (B) Lysates from
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225RSV F PROTEIN EXPRESSION USING AN HRV VECTORImmunization of mice with HeLa cell lysates
transfected with DP1FVP3 induces neutralizing
antibodies to RSV
The only in vivo systems available for testing immuni-
ations with packaged rhinovirus vectors are chimpan-
ees and humans. We are currently developing a proto-
ol to test our packaged rhinovirus replicons in a primate
odel. However, in an effort to initially determine
hether the F protein produced by DP1FVP3 was capa-
le of inducing neutralizing antibodies against RSV, we
mmunized Balb/c mice with lysates of HeLa cells that
ad been transfected with DP1FVP3. Serum was col-
ected 2 weeks following a booster immunization and
ested for the presence of RSV neutralizing antibody as
escribed under Materials and Methods. The results
Table 1) show that the serum from each of four immu-
ized mice produced significant titers of neutralizing
ntibodies to RSV, ranging from 64 to $256. In contrast,
erum from mice that had been immunized with lysates
f cells transfected with an unrelated HRV replicon
DP1Luccre) or mock-transfected cells did not contain any
etectable RSV neutralizing antibodies (titer ,2, Table 1).
hus, the F protein produced from DP1FVP3 induces an
ppropriate immune response that is effective in neutral-
zing RSV.
DISCUSSION
We have shown in ribonuclease protection assays that
he HRV-14 replicon DP1FVP3, which contains the gene
or a membrane glycoprotein (F protein) of RSV, is able to
eplicate following transfection in H1-HeLa cells. The
xpression and limited processing of the F protein in
P1FVP3 RNA-transfected cells (or cells infected with
ackaged replicon RNA) were confirmed by immunoblot
nalysis and indirect immunofluorescence. Expression
TABLE 1
Anti-RSV Neutralizing Antibody Response of Mice Immunized with
Lysates from DP1FVP3 Replicon-Transfected Cells
Immunogena Mouse Reciprocal serum antibody titer to RSV
DP1FVP3 1 64
2 128
3 64
4 $256
DP1Luccre 5 ,2
Mock 6 ,2
a Serum collected from mice that had been immunized intraperito-
eally with the indicated replicon RNA was tested for the presence of
nti-RSV antibodies as described under Materials and Methods. Four
ice were immunized with DP1FVP3 lysate, and one each with
P1Luccre lysate or normal HeLa lysate.f the F protein was dependent on replication of the
P1FVP3 RNA. Glycosidase digestions indicated that all
b
af the F protein produced was glycosylated, but both the
olgi-specific modification of the N-linked carbohydrate
ide chains and the proteolysis of the F0 precursor into
he mature F1 and F2 subunits were impaired. However,
ven though most of the expressed product was not
ompletely processed, the F protein produced following
ransfection with DP1FVP3 was capable of inducing neu-
tralizing antibodies to RSV when used to immunize mice.
Earlier work by Lu et al. (1995) suggested that in the
context of a dicistronic PV expression vector, the pres-
ence of the T-cell receptor CD4 signal sequence from
HIV-1 gp120 inhibited early steps of viral replication,
probably due to the sequestration of the viral polysome
in the rough ER. Since the inclusion of the CD4 trans-
membrane domain did not restore replication, which
could only be accomplished by removal of the signal
sequence, the authors concluded that PV vectors in gen-
eral are unable to express glycosylated proteins. Simi-
larly, Ansardi et al. (1994) reported that insertion of the
sequence for carcinoembryonic antigen (CEA) into PV
replicons abolished replication, and that replication
could be restored by deletion of the CEA signal se-
quence. In contrast, more recent studies using PV repli-
cons or monocistronic recombinant PV constructs have
suggested that these vectors were indeed able to ex-
press foreign proteins that were glycosylated (Anderson
et al., 1996, 1997; Tang et al., 1997). However, expression
of the RSV F protein by the DP1FVP3 replicon provides
additional evidence of possible limitations of picornavi-
rus-based expression of glycoproteins: since the F pro-
tein is processed in the Golgi compartment by a cellular
furin-like protease, we were able to determine that pro-
tein modifications occurring past the ER may be re-
stricted. We speculate that this restriction is due to the
membrane alterations carried out by the viral 2B or 3A
proteins (Aldabe et al., 1996; Barco and Carrasco, 1995;
Doedens et al., 1997; Doedens and Kirkegaard, 1995).
Nevertheless, the partially processed F protein ex-
pressed from DP1FVP3 remained immunogenic, which
further supports the idea that picornavirus vectors are
suitable for expression of medically important foreign
glycoproteins as immunogens.
The replication competence of our construct probably
derives from the efficient stop-transfer activity of the
transmembrane domain of the F protein, which results in
the downstream artificial 3Cpro cleavage site being lo-
ated in the cytoplasm and accessible to the viral pro-
ease. We also constructed similarly configured HRV-14
eplicons, DP1SEAPVP3 and DP1HGHVP3, which con-
ain the genes for secreted alkaline phosphatase (SEAP)
nd human growth hormone (HGH), respectively. Neither
eplicon is able to replicate following transfection in
1-HeLa cells (McKnight, 1999; Mosier, 1997). Since the
EAP and HGH glycoproteins do not contain transmem-
rane domains it may be possible, as suggested by Lu et
l. (1995), that the engineered 3Cpro cleavage site at the
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226 DOLLENMAIER ET AL.C-terminus of SEAP or HGH is translocated into the ER
during translation, becoming inaccessible to the viral
protease and fixing the unprocessed viral polyprotein in
an environment that would not be conducive to viral
replication. Alternatively, we have noted from Kyte and
Doolittle analysis (Kyte and Doolittle, 1982) that the SEAP
and HGH proteins have significantly lower hydropathic
indexes when compared to the RSV F protein (22.85 and
22.69 versus 20.38). Thus, it is interesting to speculate
that the more hydrophilic glycoproteins migrate more
quickly into the vesicular transport compartment, which
would similarly place the viral polyprotein within the ER.
Taken together, these data strongly suggest that there
are limitations on the foreign sequences that can be
successfully inserted into HRV genomes and that the
replication capacity of a replicon depends on the specific
foreign sequence inserted.
The RSV F protein is synthesized as a glycosylated 68-
to 70-kDa F0 precursor that undergoes post-translational
maturation in the Golgi compartment. F0 forms an oli-
gomer in the rough ER and is cleaved in the trans-Golgi
compartment by a cellular endoprotease (furin) to form
disulfide-linked F1 and F2 subunits (Collins and Mottet,
1991; Gotoh et al., 1992). The mature F protein is finally
xpressed at the cell surface forming a viral envelope
etramer spike (Collins et al., 1996). In cells supporting
eplication of the DP1FVP3 RNA replicon, the F protein
ould be detected as a 66-kDa F0 precursor, indicating
hat the artificial 3CDpro cleavage site at the C-terminus of
he protein was efficiently processed. However, the pre-
ominance of the F0 form when compared to the expres-
ion level of the mature, F1 48-kDa glycoprotein sug-
ested that the furin proteinase processing of the pre-
ursor protein was not very efficient. This could be either
ue to differences in furin activity between HeLa and
Ep-2 cells or to impaired transport of F0 to the Golgi
ompartment. Since both cell types efficiently support
SV replication and therefore probably contain similar
evels of furin it appears more likely that there was an
nhibition of the secretory transport of the F0 precursor
rior to the trans-Golgi compartment. The susceptibility
f F0 to endo H digestion indicated that this protein was
talled in the ER and had not yet reached the medial
olgi where the N-linked carbohydrate side chains ac-
uire endo H resistance (Collins and Mottet, 1991). This
s consistent with the finding that PV protein 3A directly
locks vesicular transport from the ER to the Golgi ap-
aratus, and suggests that HRV-14 is likely to express a
rotein with a similar activity during viral replication
Doedens et al., 1997; Doedens and Kirkegaard, 1995).
An important issue for generation of replicon-based
vaccines is the development of an efficient and safe
packaging system to generate quantitative amounts of
encapsidated replicons. The PV replicons that have been
developed by Morrow and colleagues (Ansardi et al.,
1993) have been packaged by supplying capsid proteinsin trans with a recombinant vaccinia virus. The system
we used to package our HRV replicons was modified
from that described by Jia et al. (1998), and is based on
the vaccinia virus/T7 RNA polymerase hybrid expression
system. Because this method allowed us to generate
only small amounts of packaged replicons, we are cur-
rently investigating alternative methods.
In summary, data presented here indicate that HRV-14
replicons are able to express clinically relevant secreted
glycoproteins and provide further support for the use of
HRV replicons as a vaccine delivery system. It has re-
cently been shown that neutralizing antibodies gener-
ated during RSV infection have greater affinity for virion F
protein when compared to purified F protein or to that
present in lysates of RSV-infected cells (Sakurai et al.,
1999). Therefore, it appears that it is critical to deliver the
mature oligomeric F protein as an immunogen in order to
induce a strong RSV-neutralizing immune response. Our
data indicate that the DP1FVP3 replicon expresses
readily detectable amounts of F protein, and initial stud-
ies indicate that the antigen produced is able to stimu-
late a neutralizing humoral immune response in mice.
Further work will be required to determine whether pack-
aged DP1FVP3 RNA can be delivered to the upper re-
spiratory tract and elicit similar immune responses in
primates.
MATERIALS AND METHODS
Cells, viruses, and antibodies
H1-HeLa and HEp-2 cells were obtained from the
American Type Culture Collection (ATCC) and were
maintained in 13 minimal essential medium (MEM) sup-
plemented with Earle’s salts (GIBCO/BRL), L-glutamine,
and 10% fetal calf serum (MEM-10). Dr. Bernard Moss
(National Institutes of Health, Bethesda, MD) provided
recombinant vaccinia virus vTF7-3 and a stock was pro-
duced using previously described techniques (Moss and
Earl, 1998). Dr. Roberto Garofalo (University of Texas
Medical Branch at Galveston) provided stocks of the A2
strain of RSV. Monoclonal anti-peptide antibody RF78
was a kind gift from Dr. Ping-Chuan Hu, University of
North Carolina at Chapel Hill, and was directed against
amino acids 269–277 of the F1 subunit of the F protein
(Fig. 1D). FITC-conjugated goat anti-mouse antibody was
purchased from Sigma (St. Louis, MO). Antibodies
against HRV-14 were purchased from ATCC and lucif-
erase antibodies were purchased from Sigma.
Plasmids
The coding sequence of the RSV fusion protein was
amplified by PCR from plasmid p213 that contains the F
sequence of the RSV Long strain (kindly provided by Dr.
Ping-Chuan Hu). The primers used were 59-ccacaacct-
aggccatggaccttgaaacaaagctcctcctccGTTACTAAATGCAAT-
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227RSV F PROTEIN EXPRESSION USING AN HRV VECTORATTATTTAT-39 and 59-caaccctgatcatgGAGTTGCCAATCC-39,
here lowercase bases represent HRV-14 and 3CDpro rec-
ognition sequences, the italicized bases represent unique
restriction sites (NcoI and BclI), the capitalized bases rep-
resent F-protein sequence, and the authentic HRV-14 AUG
initiator codon is indicated in boldface. The resulting PCR
product was partially digested with NcoI and BclI and li-
gated to these sites in the plasmid pSPHRV5 (McKnight
and Lemon, 1996), resulting in the fusion of the F-protein
sequence to the HRV-14 IRES. An IRES-F protein fragment
(SalI–NcoI) was removed from this intermediate plasmid
and inserted into pSPHRVLuc/VP3 (McKnight and Lemon,
1998) in lieu of the luciferase sequence, creating the
pSPHRVF/VP3 plasmid in which the 39 F-protein sequence
is fused in frame to the downstream P1 segment of HRV-14
(Fig. 1). Finally, a SalI–AvrII fragment was removed from
pSPHRVF/VP3 and ligated to these sites in pWR3.26, cre-
ating the final pDP1FVP3 replicon.
The plasmid pDP1Fdpp in which the sequence encod-
ing the downstream capsid and nonstructural proteins
were removed was utilized in constructing the pDFexp or
pDFmutexp expression vectors. Using QuikChange mu-
agenesis (Stratagene, La Jolla, CA), stop codons (UAG)
ere engineered between the last aa (Asn) of the F
rotein and the 39 NTR or between the first position aa
Gln) of the HRV-14 synthetic 3CDpro cleavage site and
the 39 NTR (Fig. 1C). The following primers and their
exact complements were used in this mutagenesis re-
action: fwt: 59-gcatttagtaacTAG ggaggaggagg-39 and
fmut: 59-ggagctttgtttcaaTAGggtccatggac-39, where the F-
protein sequence is boldfaced, the HRV-14 3CDpro cleav-
age site sequence is italicized, and the inserted stop
codons are capitalized. Successful mutagenesis was
confirmed by sequence analysis, and the selected the
pDFexp or pDFmutexp plasmids were further sequenced
o verify no other spurious mutations.
The HRV-14 capsid expression plasmid, pCap14, was
onstructed by inserting the small AatII-EcoRV fragment
f pWR3.26 into the pSP64 poly(A) vector (Promega,
adison, WI). The resulting plasmid contains the HRV-14
RES and capsid coding sequence under control of the
7 promoter and terminating with stop codon after the
ast amino acid of capsid, and a 30-nt poly(A) tract. The
onstruction of the pDP1Luc, pDP1Luc/VP3, and
DP1Luccre replicons has been described previously
(McKnight and Lemon, 1996, 1998).
In vitro transcription, transfection, and preparation of
lysates for immunization
To generate in vitro transcripts of the different repli-
cons the respective plasmids were linearized at a unique
MluI site that immediately follows the 39 terminal poly(A)
tail of the virus genome. The linear templates were used
in a previously described 100-ml in vitro transcription
eaction, and the integrity and amount of transcripts wereetermined by agarose gel analysis (McKnight and
emon, 1996). H1-HeLa cells (5 3 106) were used for
electroporation with 10–20 mg of RNA, as described
reviously, and transfected cells were plated into two
0-mm plates or four 35-mm plates containing 13 MEM-
0, and incubated at 34°C until harvest (McKnight and
emon, 1996). For the generation of F-protein-containing
ysates for mouse immunizations, 5 3 106 cells were
lated into one 100-mm plate and harvested 24 h follow-
ng transfection. Cells were removed with a scraper,
ashed 13 with PBS, and resuspended in 100 ml 13
BS. The cell suspension was subjected to three freeze/
haw cycles to break up the cells and F-protein expres-
ion was confirmed by immunoblot analysis.
ibonuclease protection assay
Ribonuclease protection assays were carried using
eagents and protocols provided with the Lysate Ribo-
uclease Protection Kit (U.S. Biochemicals). At 0, 6, 12,
nd 24 h post-transfection, transfected cell monolayers
ere washed twice with 13 PBS before the addition of
25 ml of lysis solution containing 4 M guanidine thiocy-
nate, 25 mM sodium citrate, and 0.5% sarcosyl. Lysates
ere stored at 270°C until hybridization. Riboprobes for
onitoring HRV positive-strand RNA synthesis and cel-
ular glyceraldehyde 3-phosphate dehydrogenase
GAPDH) mRNA were prepared as described previously
McKnight and Lemon, 1996); 1 3 106 cpm of each probe
was added to 45 ml of lysate and the hybridization reac-
tion was carried out overnight at 37°C. Subsequently,
lysates were digested with RNase and proteinase, and
RNA was precipitated with isopropanol. Protected RNA
duplexes were separated on 6% polyacrylamide/8 M
urea gels and visualized by autoradiography.
Immunoblot analysis
At different time points following transfection or infec-
tion, cells in 35-mm wells were removed by scraping,
washed with PBS, and pelleted by centrifugation. Cellu-
lar pellets were resuspended in 40 ml of NP-40 lysis
buffer (150 mM NaCl, 1.0% v/v NP-40, 50 mM Tris–HCl
[pH 8.0]) and incubated for 30 min on ice. The lysate was
centrifuged at maximum speed for 10 min at 4°C in a
microcentrifuge to remove debris. Ten to fifteen microli-
ters of the supernatant was separated by 8 or 10% SDS–
PAGE and subsequently transferred to a nitrocellulose
membrane. The membrane was blocked with TBS-T (TBS
[pH 7.6] with 0.1% v/v Tween-20) containing 5% w/v nonfat
dry milk for 1 h at room temperature and subsequently
washed in TBS-T. Incubation with monoclonal antibody
RF78 (diluted 1:500 in TBS-T) was for 1 h at room tem-
perature followed by three washes. The membrane was
incubated for another hour with a secondary, horserad-
ish peroxidase-conjugated sheep anti-mouse antibody
(Amersham Pharmacia Biotech, Piscataway, NJ), diluted
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228 DOLLENMAIER ET AL.1:40,000 in TBS-T. Finally, peroxidase was detected with
SuperSignal ULTRA chemiluminescence substrate
(Pierce, Rockford, IL), and immunoreactive protein bands
were visualized by exposure to X-ray film.
In situ immunostaining
H1-HeLa cells were grown in eight-well tissue culture
chamber slides and infected with packaged replicons.
Alternatively, cells were transfected with replicon RNA
and subsequently seeded on chamber slides. After over-
night incubation (14–16 h) at 34°C, cells were fixed for 2
min with cold methanol:acetone (1:1), washed with PBS,
and blocked with PBS/3% w/v BSA for 1 h at 4°C. After
three washes incubation with RF78 (1:50 diluted in
PBS/3% w/w BSA) was performed followed by washing in
PBS. A 200-fold dilution of a goat anti-mouse FITC-con-
jugated antibody (Sigma) was added and incubation was
continued for 30 min at 4°C. After a final washing step,
cells were mounted using Vectashield (Vector Laborato-
ries, Inc., Burlington, CA), coverslipped, and sealed. The
slides were examined by fluorescent microscopy.
Packaging of replicon RNAs
Generation of packaged replicons was carried out
essentially as described by Jia et al. (1998). H1-HeLa
cells (50–75% confluent) in 35- or 60-mm plates were
cotransfected with 750 ml of OPTI-MEM (GIBCO/BRL)
ontaining 6 ml Fugene transfection reagent (Roche Mo-
lecular Biochemicals, Indianapolis, IN), 2 mg each of
lasmid DNA encoding the HRV replicon, a second plas-
id, pCap14, which encodes the HRV-14 capsid proteins,
nd vTF7-3 (5 PFU/cell). Cells were incubated at 34°C for
h, washed twice with MEM (without serum), and, fol-
owing the addition of 1 to 2 ml of MEM containing 10%
BS, incubated at 34°C for 36 to 40 h. After harvesting,
he cells were lysed by addition of NP-40 to a final
oncentration of 0.5% w/v and incubation for 30 min on
ce. Cell lysates were cleared by microcentrifugation and
upernatants were adjusted to 1% w/v sarcosyl and 0.1%
/v 2-mercaptoethanol and loaded on a 1-ml sucrose
ushion (30% sucrose in 1 mM NaCl in 20 mM Tris-
cetate [pH 7.4]) and centrifuged for 2 h at 40,000 rpm
nd 16°C in an SW-41 rotor. The pellets that contained
ackaged HRV replicons were redissolved in PBS/0.1%
/v BSA and stocks of virions were stored at 280°C.
iters of packaged stocks were estimated from in situ
mmunostaining of cell monolayers infected with aliquots
f packaged virions. Multiple fields (4–6) were scored for
umbers of fluorescent cells and an average was calcu-
ated as luciferase-expressing cells per milliliter.
nzymatic deglycosylation of F protein
Cellular lysates were adjusted to 50 mM 2-mercapto-
thanol and 0.05% w/v SDS and heat-denatured for 4 min
t 100°C. After cooling, 10 ml of denatured proteins wasmixed with 3 ml 0.5 M sodium citrate (pH 5.5) and 2 to 7
ml of endo H (5 unit/ml, Roche Molecular Biochemicals)
in a total volume of 20 ml and incubated overnight at
4°C. Endo H was inactivated by heating for 5 min at
00°C and deglycosylated proteins were subsequently
eparated on a SDS/12% polyacrylamide gel and de-
ected by immunoblot. For PNGase F digestion, cellular
ysates were adjusted to 50 mM 2-mercaptoethanol and
.25% w/v SDS and heat-denatured as above. Ten micro-
iters of lysate was mixed with 5 ml 1 M Tris–HCl, pH 8.0,
.8 ml 50% v/v NP-40, and 0.2 to 1 unit of PNGase F (200
unit/ml, Roche Molecular Biochemicals) in a total of 20
ml. Overnight incubation and subsequent analysis of the
samples were done as described for the endo H treat-
ment.
Animals
Six- to 8-week-old female Balb/c mice, obtained from
Charles River Laboratories (Raleigh, NC), were used for
RSV immunization experiments. Each mouse was inoc-
ulated intraperitoneally with 100 ml of cell lysate (see
bove) mixed with an equal volume of complete Freund’s
djuvant (Sigma). Mice were boosted with 100 ml of cell
lysate mixed with an equal volume of incomplete
Freund’s adjuvant (Sigma) 2 weeks later. Thus, each
mouse was inoculated with material derived from one
100-mm dish, which corresponds to 5 3 106 cells. Mice
were bled from the lateral saphenous vein 2 weeks after
the booster immunization.
RSV neutralizing antibody assay
Serum RSV neutralizing antibody assays were carried
out in duplicate on HEp-2 cell monolayers in 96-well
tissue culture plates. Briefly, serial twofold dilutions of
heat-inactivated sera (100 ml at 30 min, 56°C) were
incubated (1 h, 37°C) with an equal volume containing
100 TCID50 RSV (A2 strain) in the presence of 10% com-
lete guinea pig complement (Sigma). The monolayers
ere inoculated with the virus–serum mixture (200 ml)
nd incubated at 37°C for 1 h to allow virus adsorption.
he inoculum was removed, complete media were
dded, and the cells were allowed to incubate at 37°C
or 4 days. Monolayers were scored for the presence or
bsence of virus infection by staining with 0.1% crystal
iolet and microscopic examination.
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